Xbrane Biopharma
Xbrane Biopharma: FDA Resubmission in 2022 (Redeye)
2022-07-04 14:16
Redeye leaves a short comment on today’s press release from Xbrane stating that the company intends to file a resubmission of its BLA for Xlucane during 2022.
info@redeye.se (Redeye.se)
Redeye AB - Redeye.se